Highlights from EAN 2021: neurodegenerative disorders

In an EAN highlights session, Professor Elisabeth Stögmann of the Medical University of Vienna, Austria, summarized key presentations from the congress regarding research in dementia.

“In 2021, the FDA approved a drug against Alzheimer’s disease (AD), and this is obviously a seismic event for our field,” Prof. Stögmann noted. “However, at present, no one can say how this will turn out in Europe. We have to wait for the decision of the European Medicines Agency, and a decision might be expected in the upcoming year.